Outcomes after induction failure in childhood acute lymphoblastic leukemia.
about
Acute lymphoblastic leukaemiaCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaChildhood Acute Lymphoblastic Leukemia: Progress Through CollaborationChildren's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia.Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Treatment of pediatric acute lymphoblastic leukemia.Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approachesLineage switching in acute leukemias: a consequence of stem cell plasticity?Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.Natural killer cell therapy in children with relapsed leukemia.HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemiaTPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways.O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapyHematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.A 50-year journey to cure childhood acute lymphoblastic leukemiaSecond malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience.Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cellsClinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignanciesThe evolution of clinical trials for infant acute lymphoblastic leukemia.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Array comparative genomic hybridization in pediatric acute leukemias.Predicting relapse risk in childhood acute lymphoblastic leukaemia.Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
P2860
Q24602387-E1DA6386-0F50-4205-8619-5F7A53821921Q28084879-8AC79BB4-1C09-4DFE-8459-A5D468B3AE72Q28087637-9D9C5EEA-0226-40A8-B82E-9A4BB104ACA8Q33711119-8F2F0188-5DBA-4443-AB08-668CE37D9E3EQ33770150-54676078-02BD-42E3-ACBA-FBFF25F9A12AQ33842087-7877E3A4-40EA-4127-9F53-9BA6C89A8F92Q34343785-D287C37B-C9FE-435B-AD08-1A718512C09BQ34820131-9A24F4B0-03C1-4D9A-85ED-D20A8E0594E6Q34820210-639C1884-7DE7-401C-98B5-667AD0AB58A2Q35070594-FF5D020E-413A-4121-BF59-303AF92F3CD5Q35178966-34325EC5-CFE0-41B7-9C21-CF806AE31F03Q35196702-30B144EE-BED7-41BB-8BEC-89563192C90AQ35723998-F487C046-A76B-4C83-80D4-CD006D6BB0F9Q35949625-6DE48DE9-F158-43FD-B250-D343728661BEQ36125000-3E221482-3A71-46EA-B231-5E5334D8CF3DQ36134458-0A214EEB-9C60-4DA1-BC79-C1697C3B290EQ36163029-60BE6291-4269-4BD4-973D-CCD528F2B264Q36169572-28BE3272-1D6B-4443-A5F5-8CA72F2C1A6AQ36251948-3E7550E0-B115-41C2-B3DA-B6F18F3ACF33Q36436934-0577A5C5-6A51-40C0-BF88-0885203045CEQ36520787-979FADAA-30E0-4E8B-AF68-3BF3D42C30B1Q36750016-887CB266-B275-401F-8D44-335C4C837B52Q36805855-EBDAAEE6-B3F2-44BB-B600-972423A4800FQ37060668-6FADC9F0-0043-4E38-AC8E-A6BD7611F2DFQ37166753-41F3E7BC-07CB-4799-9F10-BE0ABE3C35DBQ37252283-A77F99FC-BF80-4D59-B01D-ED22B39BB2BEQ37436345-BF06136F-4F71-4150-BEC7-6E85299B0699Q37503176-94F0D8B8-37A9-482B-BDC2-CE097AFB2271Q37619915-7B284656-4850-424C-8D04-8C8F815E678FQ37695012-673929F1-FDF5-4774-B5B5-B953D3BC066CQ37730023-6FEB6383-3D53-4E74-93D0-FADEA21CF143Q38033592-64324256-5834-4FDE-8897-C07D6AC900B6Q38079288-40538545-32D1-4661-9D54-35D95778B6B3Q38113815-AB4BFF22-A5A1-4D11-9CAA-D07F3BE56114Q38117685-E4C745B5-CF92-4F70-8CC4-62DCA7F862EDQ38173985-2D2C7284-F1F8-4917-9F86-2E7B56F08710Q38220573-A233C76E-EE6C-4E0C-BBEF-1A75B870F83AQ38264774-F42C8DEB-936E-4721-886C-73E91CAAE23EQ38669037-C277D049-CFA1-43FF-BA55-6B28FADD641AQ38686308-513EBD9E-E073-4BD4-95D9-81622543BD09
P2860
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@ast
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@en
type
label
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@ast
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@en
prefLabel
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@ast
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@en
P2093
P2860
P50
P356
P1476
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
@en
P2093
Akira Ohara
André Baruchel
Anne Birgitta Versluys
Bruce M Camitta
Georg Mann
Hansjörg Riehm
Jacques Otten
Jochen Harbott
Keizo Horibe
Lewis B Silverman
P2860
P304
P356
10.1056/NEJMOA1110169
P407
P577
2012-04-01T00:00:00Z